Finally, the outcome of a meta-analysis of 72 trials reporting information on diabetic ketoacidosis (DKA) in patients with T2D receiving SGLT-2 inhibitors, of which 9 trials observed at least one case of ketoacidosis, provided reassurance that, when these drugs are appropriately prescribed, there is negligible risk of DKA [79]. This evidence concerns the gene SLC5A2 and diabetes mellitus.